Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA) will participate in the 2021 Jefferies London Healthcare Conference on November 18-19, 2021. Management will host a fireside chat and one-on-one investor meetings, with the chat available on-demand from November 18. The company focuses on developing precision oncology therapies to combat tumor resistance, featuring their proprietary SNÅP platform. Their lead product, TYRA-300, targets bladder cancer, while TYRA-200 aims at intrahepatic cholangiocarcinoma.

CARLSBAD, Calif., Nov. 10, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will participate in a fireside chat and host one-on-one investor meetings during the virtual portion of the 2021 Jefferies London Healthcare Conference, taking place November 18-November 19, 2021. The fireside chat will be available on-demand for attendees during the virtual conference beginning on Thursday, November 18, 2021.

A webcast of the fireside chat will be available on the Company's website at https://tyra.bio in the "For Investors" section following conclusion of the conference.  

About Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors. 

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. TYRA cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. TYRA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of TYRA in general, see the risks described in our prior filings with the U.S.  with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our most recent quarterly report on Form 10-Q and any subsequent filings with the SEC.

Contact:

Amy Conrad
aconrad@tyra.bio

View original content:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-the-2021-jefferies-london-healthcare-conference-301421548.html

SOURCE Tyra Biosciences, Inc.

FAQ

What is the date of Tyra Biosciences' participation in the 2021 Jefferies London Healthcare Conference?

Tyra Biosciences will participate in the 2021 Jefferies London Healthcare Conference on November 18-19, 2021.

What is the focus of the fireside chat by Tyra Biosciences at the conference?

The fireside chat will focus on Tyra's precision oncology therapies and their innovative SNÅP platform.

Where can I find the webcast of Tyra Biosciences' fireside chat?

The webcast will be available on Tyra Biosciences' website under the 'For Investors' section following the conclusion of the conference.

What are the lead products of Tyra Biosciences?

Tyra Biosciences' lead products include TYRA-300, an FGFR3 inhibitor for bladder cancer, and TYRA-200, an FGFR2 inhibitor for intrahepatic cholangiocarcinoma.

What is the significance of the SNÅP platform for Tyra Biosciences?

The SNÅP platform enables rapid and precise refinement of therapies to address drug resistance in cancer treatment.